Q-omics provides the consensus-scored TAAR1 profile across patient tissues and cancer cell-line models. TAAR1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAAR1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TAAR1 RNA expression shows 7,369 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, KICH, and ESCA as cancer lineages where TAAR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAAR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAAR1 survival associations across molecular data types. TAAR1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAAR1 RNA expression–survival associations across cancer types. High TAAR1 expression shows unfavorable associations in STAD, MESO and KIRP, but favorable associations in KIRC, HNSC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAAR1 RNA expression.
This table summarizes TAAR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TAAR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAAR1 shows lower tumor expression in KICH, KIRP, HNSC, THCA, UCEC and PRAD. The KICH box plot shows higher TAAR1 RNA expression in normal versus tumor tissue (log2 FC = −0.330, t-test p < 0.001).
This table shows molecular features associated with TAAR1 in patient tissues and cancer cell lines. In patient samples, TAAR1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TAAR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
